Led by new CEO Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals has a stated ambition to transition the RNA interference therapeutics trailblazer to a top 5 biotech – measured by market capitalization – within the next five years.
Emergent BioSolutions came into 2022 after a challenging year that saw the company lose a lucrative contract with the U.S. government following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine.
Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Since acquiring Allergan for $63 billion in 2019, AbbVie said it’s “tracking well” against the financial commitment the company made when striking the deal. Chief Financial Officer Rob Michael said at the 2022 J.P. Morgan Healthcare Conference the company is exceeding AbbVie’s revenue expectations in the aesthetics market, led by Botox.
Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start with deal announcements and plans to drive biopharma companies through the year.
J.P. Morgan Chase put an end to the uncertainty surrounding its annual health care conference, announcing that the 40th edition will move to a virtual format.
As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.
BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”